Guardant Health, Inc.
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG006D97VY9
GH
Guardant Health, Inc.
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Diagnostics & Research
NAME
Guardant Health, Inc.
ISIN
US40131M1099
TICKER
GH
MIC
XNAS
REUTERS
GH.OQ
BLOOMBERG
GH US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Wed, 13.11.2024
Guardant Health
US40131M1099
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 22, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 233,603 shares of its common stock to 123 new non-executive employees and non-qualified stock option aw...
Guardant Health
Wed, 06.11.2024
Guardant Health
US40131M1099
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024.
Third Quarter 2024 Financial Highlights
Recorded revenue of $191.5 million for the third quarter of 2024, an increase of 34% over the third quarter of 2023
Reported 53,100 clinical tests (excludi...
Guardant Health
Fri, 01.11.2024
Guardant Health
US40131M1099
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences.
●
Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA
Fireside chat on Tuesday, November 12 at 10:30 a.m. Eastern Time
●
...
Guardant Health
Wed, 30.10.2024
Guardant Health
US40131M1099
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the inclusion of its blood-based colorectal cancer screening product Shield in TIME’s annual list of the Best Inventions, which features 200 extraordinary innovations changing lives.
To compile this year's list, TIME solicited nominations from TIME editors a...
Guardant Health
Mon, 28.10.2024
Guardant Health
US40131M1099
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data supporting the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening adherence at the American College of Gastroenterology (ACG) 2024 Annual Meeting in Philade...
Guardant Health
Thu, 24.10.2024
Guardant Health
US40131M1099
Guardant Health, Inc. (Nasdaq: GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies.
“We a...
Guardant Health
Tue, 15.10.2024
Guardant Health
US40131M1099
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the web...
Guardant Health
Wed, 18.09.2024
Guardant Health
US40131M1099
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the peer-reviewed journal Nature Medicine published results from the SCRUM-Japan GOZILA study confirming that selecting targeted therapy on the basis of Guardant360® CDx liquid biopsy results may significantly extend survival for patients with advanced cancer...
Guardant Health
Fri, 13.09.2024
Guardant Health
US40131M1099
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024.
Data on the Gua...
Guardant Health
Tue, 10.09.2024
Guardant Health
US40131M1099
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with the Agostino Gemelli University Polyclinic Foundation IRCCS (“Policlinico Gemelli”) to establish an in-house liquid biopsy testing service as a part of its diagnostics services within its hospital system. Leveraging Guardant Health’s cuttin...
Guardant Health
Information on product placements
